Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2010

View Archived Issues

Sanofi-aventis reports Q4 and full-year results for 2009

Matrix Laboratories claims new TRPV1 receptor antagonists as analgesics

TopoTarget describes new nicotinamide phosphoribosyltransferase inhibitors

Organon and Pharmacopeia disclose novel LXR ligands

Leo Pharma presents novel VEGFR-2 inhibitors

Novel SMO receptor antagonists described by Italian researchers

Tekmira provides corporate update and results 2009

Otilonium bromide improves irritable bowel syndrome symptoms

ONCOFID-P-B well tolerated and active in phase I trial in refractory bladder carcinoma

Data on OX1/OX2 orexin receptor antagonist MK-4305 presented at ACS Meeting

Colestilan monotherapy improves glycemic and cholesterolemic control in type 2 diabetes

First-in-human clinical data on Mttp inhibitor JNJ-16269110 presented at ASCPT meeting

Preclinical data on new GlyT-1 inhibitor RG-1678 presented at ACS meeting

Novavax reports on 2009 A/H1N1 VLP pandemic flu vaccine

EMA accepts Cinryze MAA for hereditary angioedema for filing

ChemGenex provides update on regulatory status of Omapro

Aastrom treats final patient in phase IIb RESTORE-CLI trial of vascular repair cells

Arena begins phase I trial of APD-916 for narcolepsy and cataplexy

Poniard redirects regulatory efforts for picoplatin

Othera reports phase I/II data on OT-551 in age-related macular degeneration

Vernalis announces topline phase IIb results on V-3381 for neuropathic pain in diabetes

Preliminary phase IIb data on Sativex in cancer pain support entry into phase III

Human Genome Sciences reports interim phase IIb results on Zalbin in hepatitis C

FDA orphan drug designation for Diamyd's rhGAD65 in type 1 diabetes with residual beta-cell function

Salix's Xifaxan approved in U.S. for reducing risk of overt hepatic encephalopathy recurrence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...